Brought to you by 
NewLink partners immune checkpoint inhibitor NLG919 with Genentech; rights returned; terminated
09 Nov 2021
Executive Summary
In the company’s first validating deal, NewLink Genetics Corp. (cancer immunotherapy) licensed Roche’s Genentech Inc. exclusive worldwide rights to its Phase I immune checkpoint indoleamine 2,3-dioxygenase (IDO) inhibitor NLG919 for solid tumors. NLG919 works by de-activating T-cells that enable tumors to evade immune system attacks.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NewLink partners immune checkpoint inhibitor NLG919 with Genentech; rights returned; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice